medigraphic.com
ISSN 2007-6509 (Print)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2010, Number S1

<< Back Next >>

Rev Mex Med Transfus 2010; 3 (S1)

Therapy of iron chelation

López SN

Language: Spanish
References: 24
Page: 80-86
PDF size: 224.59 Kb.


ABSTRACT

The iron (Fe) is a necessary metal for enzymatic systems function. Most of iron is contained into hemoglobin and it’s function is gaseous exchange between tissue and lung; in other enzymatic systems iron takes part in different oxide-reduction mechanism. During normal physiology, quantity of iron absorbed (2 mg/d) is lost by sloughing of intestinal mucosa and skin, in a close equilibrium. This quantity is insufficient for maintain the erythropoiesis, that use the iron from the physiologic hemolysis, 18 mg/day; this iron has no other active mechanism for the excretion. In patients transfusion-dependent there is an iron excess approximately 3.46 mg/g of hemoglobin transfused or 250 mg/unit. The iron from the hemolysis is binding to ferritin and hemosyderin, when this proteins are full there is iron overload and gradually accumulates in several tissues: in the liver at first, but when it stands in high levels it’s deposited in any organs such as heart, glands, ganglion, skin, etc., and more danger, could stay free as non binding transferring iron (NBTI), the most toxic iron form to the human. The use of different substances that binding the iron and help for excretion it, are the best option for limit iron toxicity. Actually we have different substances for this objective: deferoxamine, deferiprone and deferasirox.


REFERENCES

  1. Hall JE. Chapter 32 Red blood cells, anemia and polycithemia. Guyton and Hall Phsiology Review, Ed. Elsevier Saunders 2006: 419-28.

  2. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15-9.

  3. Andrews NC. Disorders of iron metabolism. NEJM 1999; 341: 1986-95.

  4. Fairbanks VF, Beutler E. Iron Metabolism en Williams Hematology, Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U Ed. 6th Edition, 2001: 295-304.

  5. Porter J. Concepts and goals in the management of transfusional iron overlosad. American Journal of Hematology 2007: 82.

  6. Kwiatkowski JJ, Cohen AR. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemia’s. Hematol Oncol Clin N Am 18 (2004) 1355-1377.

  7. Maggio A et al. Blood Cells Mol Dis 2002; 28 (2): 196-208.

  8. Choudry VP, Naithani R. Current status of iron overload and chelation with deferasirox. Indian J Ped 2007; 74: 759-764.

  9. Porter J. Concepts and goals in the management of transfusional iron overlosad; American Journal of Hematology; 82, 2007.

  10. Hershko C. Iron loading and its clinical implications; American Journal of Hematology 2007.

  11. Schafer AI, Cheron RG, Dluhy R et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319-24.

  12. Zurlo MG, De Stefano P, Borgna-Pignatti C et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2: 27-30.

  13. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850: 227-31.

  14. Aldouri MA, Wonke B, Hoffbrand AV et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84: 113-7.

  15. Aessopos A, Farmakis D, Karagiorga M et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97: 3411-6.

  16. Batra AS, Acherman RJ, Wong WY et al. Cardiac abnormalities in children with sickle cell anemia. Am J Hematol 2002; 70: 306-12.

  17. The Management of Sickle Cell Disease. U.S. Department of Health and Human Services. Division of Blood Disorders and Resources. NIH publication No. 04-2117.

  18. Kushner JS, Porter JP, Olivieri NF. Secondary Iron Overload, Hematology 2001; 47-61.

  19. Kwiatkowski JJ, Cohen AR. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias. Hematol Oncol Clin N Am 2004; 18: 1355-1377.

  20. Al-Refaie FN et al. Br J Haematol 1995; 89 (2): 403-8.

  21. Choudry VP, Naithani R. Current status of iron overload and chelation with deferasirox. Indian J Ped 2007; 74: 759-764.

  22. Maggio A et al. Blood Cells Mol Dis 2002; 28 (2): 196-208.

  23. Anderson LJ et al. Lancet 2002; 360 933d: 516-520.

  24. Cohen AR. New advances in iron chelation therapy. In Hematology. American Society of Hematology. 2006: 42-47.




2020     |     www.medigraphic.com